Inhibition of cell growth and Epstein-Barr virus reactivation by CD40 stimulation in Epstein-Barr virus-transformed B cells

Viral Immunology

Volumn 13, Issue 2, 2000, Pages 215-229

  Fukuda, Makoto ^a   Satoh, Tomohis A ^a   Takanashi, Masakatu ^b   Hirai, Kanji ^b   Ohnishi, Eiko ^a   Sairenji, Takeshi ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; EARLY ANTIGEN; GENE PRODUCT; RNA;

ARTICLE; B LYMPHOCYTE; CELL TRANSFORMATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GROWTH INHIBITION; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NONHUMAN; PROTEIN CROSS LINKING; SIGNAL TRANSDUCTION; VIRUS REACTIVATION;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 0033917039     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2000.13.215     Document Type: Article

References (50)

1. Armitage, R.J., C.R. Maliszewski, M.R. Alderson, K.H. Grabstein, M.K. Spriggs, and W.C. Fanslow. CD40L: A multi-functional ligand. Semin. Immunol. 5:401-412.
2. Baichwal, V.R., and B., Sugden 1988. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene. 2:461-467.
3. Banchereau, J., F. Bazan, D. Blanchard, F. Briere, J.P. Galizzi, C. van Kooten, Y.J. Liu, F. Roussset, and S. Saeland. 1994. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12:881-922.
4. Blanchard, D.A., M.T. Affredou, and A. Vazquez. 1997. Modulation of the p27-kipl cyclin-dependent kinase inhibitor expression during IL-4-mediated human B cell activation. J. Immunol. 158:3054-3061.
5. Brousset, P., D. Schlaifer, D. Roda, P. Massip, B. Marchou, and G. Delsol. 1996. Characterization of Epstein-Barr virus-infected cells in benign lymphadenopathy of patients seropositive for human immunodeficiency virus. Hum. Pathol. 27:263-268.
6. Cohen, J.J., and R.C. Duke. 1984. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J. Immunol. 132:38-42.
7. Countryman, J., H. Jenson, R. Seibl, H. Wolf, and G. Miller. 1987. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61:3672-3679.
8. Diabata, M., I. Mellinghoff, S. Takagi, R.E. Humphreys, and T. Sairenji. 1991. Effect of genistein, a tyrosine kinase inhibitor, on latent EBV activation induced by cross-linkage of membrane IgG in Akata B cells. J. Immunol. 147:292-297.
9. Erickson, K.D., and J.M. Martin. 1997. Early detection of the lytic LMP-1 protein in EBV-infected B-cells suggests its presence in the virion. Virology, 234:1-13.
10. Falk, K., I. Ernberg, R. Sakthivel, J. Davis, B. Christensson, J. Luka, M. Okano, H.L. Grierson, G. Klein, and D.T. Purtilo. 1990. Expression of Epstein-Barr virus encoded proteins and B-cell markers in fatal infectious mononucleosis. Int. J. Cancer. 46:976-984.
11. Farrell, P.J. Epstein-Barr virus immortalizing genes. 1995. Trends Microbiol. 3:105-109.
12. Farrington, M., L.S. Grosmaire, S. Nonoyama, S.H. Fischer, D. Hollenbaugh, J.A. Ledbetter, R.J. Noelle, A. Aruffo, and H.D. Ochs. 1994 CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc. Natl. Acad. Sci. USA. 91:1099-1103.
13. Funakoshi, S., D.L. Longo, M. Beckwith, D.K. Conley, G. Tsarfaty, I. Tsarfaty, R.J. Armitage, W.C. Fansolow, M.K. Spriggs, and W.J. Murphy. 1994. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood. 83:2787-2794.
14. Garrone, P., E.M. Neidhardt, E. Garcia, L. Galibert, C. van Kooten, and J. Banchereau. 1995. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J. Exp. Med. 182:1265-1273.
15. Gregory, C.D., C. Dive, S. Henderson, C.A. Smith, G.T. Williams, J. Gordon, and A.B. Rickinson. 1991. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature. 349:612-614.
16. Hamilton Dutoit, S.J., D. Rea, M. Raphael, K. Sandvej, H.J. Delecluse, C. Gisselbrecht, L. Marelle, H.J. van Krieken, and G. Pallesen. 1993. Epstein-Barr virrus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am. J. Pathol. 143:1072-1085.
17. Han, H., T. Nomura, T. Honjo, and T. Tsubata. 1996. Differential modulation of cyclin-dependent kinase inhibitor p27Kip1 by negative signaling via the antigen receptor of B cells and positive signaling via CD40. Eur. J. Immunol. 26:2425-2432.
18. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805-816.
19. Henderson, S., M. Rowe, C. Gregory, D. Croom Carter, F. Wang, R. Longnecker, E. Kieff, and A. Rickinson. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 65:1107-1115.
20. Hill, A., and H. Chapel. 1993. X-linked immunodeficiency. The fruits of cooperation [news; comment]. Nature. 361:494.
21. Kaplan, L.D., D.I. Abrams, E. Feigal, M. McGreath, J. Kahn, P. Neville, J. Ziegler, and P.A. Volberding. 1989. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA. 261:719-724.
22. Kato, J.Y., M. Matsuoka, K. Polyak, J. Massague, and C.J. Sherr. 1994. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 79:487-496.
23. Kelly, K., and K.A. Knox. 1995. Differential regulatory effects of cAMP-elevating agents on human normal and neoplastic B cell functional response following ligation of surface immunoglobulin and CD40. Cell. Immunol. 166:93-102.
24. Kenney, S., J. Kamine, E. Holley Guthrie, J.C. Lin, B.C. Mar, and J. Pagano. 1989. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J. Virol. 63:1729-1736.
25. Kersten, M.J., J. Van Gorp, S.T. Pals, F. Boon, and M.H. Van Oers. 1998. Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: Correlation with histology and CD4-cell number. Leuk. Lymphoma. 30:515-524.
26. Klaus, G.G., M.S. Choi, and M. Holman. 1994. Properties of mouse CD40. Ligation of CD40 activates B cells via a Ca(++)-dependent, FK506-senstive pathway. Eur. J. Immunol. 24:3229-3232.
27. Klein, G., and E. Klein. 1985. Evolution of tumours and the impact of molecular oncology. Nature. 315:190-195.
28. Klein, G., B. Giovanella, A. Westman. J.S. Stehlin, and D. Mumford. 1975. An EBV-genome-negative cell line established from an American Burkitt lymphoma: Receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology. 5:319-334.
29. Knox, K.A., and J. Gordon. 1993. Protein tyrosine phosphorylation is mandatory for CD40-mediated rescue of germinal center B cells from apoptosis. Eur. J. Immunol. 23:2578-2584.
30. Lagresle, C., C. Bella, P.T. Daniel, P.H. Krammer, and T. Defrance. 1995. Regulation of germinal center B cell differentiation. Role of the human APO-1/Fas (CD95) molecule. J. Immunol. 154:5476-5456.
31. Lam, M., G. Dubyak, L. Chen, G. Nunez, R.L. Miesfeld, and C.W. Distelhorst. 1994. Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc. Natl. Acad. Sci. USA. 91:6569-6573.
32. Laman, J.D., E. Claassen, and R.J. Noelle. 1994. Immunodeficiency due to a faulty interaction between T cells and B cells. Curr. Opin. Immunol. 6:636-641.
33. Ledbetter, J.A., G. Shu, M. Gallagher, and E.A. Clark. 1987. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40). J. Immunol. 138:788-794.
34. Levine, A.M., J. Sullivan Halley, M.C. Pike, M.U. Rarick, C. Loureiro, M. Bernstein Singer, E. Willson, R. Brynes, J. Parkers, S. Rasheed, and P.S. Gill. 1991. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer. 68:2466-2472.
35. Liu, Y.J., D.E. Joshua, G.T. Williams, C.A. Smith, J. Gordon, and I.C. MacLennan. 1989. Mechanism of antigen-driven selection in germinal centres. Nature. 342:929-931.
36. Miller, C.L., A.L. Burkhardt, J.H. Lee, B. Stealey, R. Longnecker, J.B. Bolen, and E. Kieff. 1995. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity. 2:155-166.
37. Miller, C.L., J.H. Lee, E. Kieff, and R. Longnecker. 1994. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc. Natl. Acad. Sci. USA. 91:772-776.
38. Miyashita, E.M., B. Yang, G.J. Babcock, and D.A. Thorley Lawson. 1997. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 71:4882-4891.
39. Murphy, W.J., S. Funakoshi, M. Beckwith, S.E. Rushing, D.K. Conley, R.J. Armitage, W.C. Fanslow, H.C. Rager, D.D. Taub, F.W. Ruscetti, and D.L. Longo. 1995. Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphogenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Blood. 86:1946-1953.
40. Nonoyama, S., D. Hollenbaugh, A. Aruffo, J.A. Ledbetter, and H.D. Ochs. 1993. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J. Exp. Med. 178:1097-1102.
41. Notarangelo, L.D., Duse, M., and Ugazio, A.G. 1992. Immunodeficiency with hyper IgM (HIM). Immunodef. Rev. 3:101-121.
42. Ohnishi, E., T. Iwata, S. Inouye, T. Kurata, and T. Sairenji. 1997. Interleukin-4 production in Epstein-Barr virus-transformed B cell lines from peripheral mononuclear cells of patients with atopic dermatitis. J. Interferon Cytokine Res. 17:597-602.
43. Okano, M., G.M. Thiele, J.R. Davis, H.L. Grierson, and D.T. Purtilo. 1988. Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin. Microbiol. Rev. 1:300-312.
44. Ometto, L., C. Menin, S. Masiero, L. Bonaldi, A. Del Mistro, A.M. Cattelan, E. D'Andrea, A. De Rossi, and L. Chieco Bianchi. 1997. Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood. 90:313-322.
45. Polyak, K., M.H. Lee, H. Erdjument Bromage, A. Koff, J.M. Roberts, P. Tempst, and J. Massague. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:59-66.
46. Rathmell, J.C., M.P. Cooke, W.Y. Ho, J. Grein, S.E. Townsend, M.M. Davis, and C.C. Goodnow. 1995. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature. 376:181-184.
47. Rickinson, A.B., and E. Kieff., 1996. Epstein-Barr virus, pp 2397-2446. in: Fields, B.N., D.M. Knipe, P.M. Howley, et al. Fields virology. 3rd ed. Lippincott-Raven. Philadelphia, PA.
48. Rowe, M., A.L. Lear, D. Croom Carter, A.H. Davies, and A.B. Rickinson. 1992. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66:122-131.
49. Sellins, K.S., and J.J. Cohen. 1987. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J. Immunol. 139:3199-3206.
50. Shapiro, R.S., K. McClain, G. Frizzera, K.J. Gajl Peczalska, J.H. Kersey, B.R. Blazar, D.C. Arthur, D.F. Patton, J.S. Greenberg, B. Burke, N.K.C. Ramsay, P. McGlave, and A.H. Filipovich. 1988. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 71:1234-1243.